About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Cd19
CD19 antigen
MGI:88319
238 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Adam10tm1.1Dhc/Adam10tm1.1Dhc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL 		abnormal B cell differentiation J:158127
absent marginal zone B cells J:158127
decreased transitional stage T2 B cell number J:158127
increased follicular B cell number J:158127
increased transitional stage T1 B cell number J:158127
Bak1tm1Thsn/Bak1tm1Thsn
Baxtm1Sjk/Baxtm2Sjk
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ 		abnormal B cell number J:100463
abnormal B cell physiology J:100463
decreased marginal zone B cell number J:100463
increased B cell number J:100463
increased B-2 B cell number J:100463
increased bone marrow cell number J:100463
increased follicular B cell number J:100463
increased IgA level J:100463
increased IgG level J:100463
increased IgM level J:100463
increased immunoglobulin level J:100463
increased pre-B cell number J:100463
increased pro-B cell number J:100463
increased transitional stage B cell number J:100463
Bcl10tm1Mak/Bcl10tm1Mak
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd 		normal immune system phenotype J:228288
normal mortality/aging J:228288
Birc2tm1Rbr/Birc2tm1Rbr
Birc3tm1.1Rbr/Birc3tm1.1Rbr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * NZB 		decreased B cell apoptosis J:172843
decreased germinal center B cell number J:172843
decreased spleen germinal center size J:172843
enlarged lymph nodes J:172843
enlarged spleen J:172843
increased B cell number J:172843
increased follicular B cell number J:172843
increased marginal zone B cell number J:172843
Birc2tm1Rbr/Birc2tm1Rbr
Birc3tm1.1Rbr/Birc3tm1.1Rbr
Cd19tm1(cre)Cgn/Cd19+
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 * NZB 		normal immune system phenotype J:172843
Birc2tm1Rbr/Birc2tm1Rbr
Birc3tm1Rbr/Birc3tm1Rbr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * NZB 		normal immune system phenotype J:172843
Blmtm4Ches/Blmtm4Ches
Cd19tm1(cre)Cgn/Cd19+
Nsmce2tm2.1Ofc/Nsmce2tm2.1Ofc
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL 		abnormal B cell morphology J:227197
abnormal B cell physiology J:227197
decreased B cell number J:227197
elevated level of mitotic sister chromatid exchange J:227197
small spleen J:227197
Blmtm4Ches/Blmtm4Ches
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac 		abnormal class switch recombination J:194603
Blnktm1Dkit/Blnktm1Dkit
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
involves: 129P2/OlaHsd * C57BL/6 * NZB 		abnormal pre-B cell morphology J:84040
absent immature B cells J:84040
absent mature B cells J:84040
arrested B cell differentiation J:84040
decreased pre-B cell number J:84040
enlarged lymph nodes J:84040
enlarged spleen J:84040
increased leukemia incidence J:84040
Bod1lem1Bltn/Bod1lem1Bltn
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6J 		decreased IgG1 level J:337726
decreased IgG level J:337726
Brca1tm2Cxd/Brca1tm2Cxd
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac 		chromosome breakage J:197442
Brca1tm2Cxd/Brca1tm2Cxd
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac 		normal cellular phenotype J:197442
Brca2tm1Brn/Brca2tm1Brn
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd 		chromosome breakage J:197442
Brca2tm1Brn/Brca2tm1Brn
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd 		chromosome breakage J:197442
Casp8tm1Hed/Casp8tm1Hed
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd 		abnormal adaptive immunity J:116713
abnormal immunoglobulin level J:116713
decreased B cell number J:116713
decreased B cell proliferation J:116713
decreased B-1 B cell number J:116713
decreased marginal zone B cell number J:116713
increased apoptosis J:116713
spleen hypoplasia J:116713
Cd19tm1(cre)Cgn/Cd19+
Faslpr/Fastm1Cgn
involves: 129P2/OlaHsd * C57BL/6 * MRL 		enlarged lymph nodes J:114948
enlarged spleen J:114948
Cd19tm1(cre)Cgn/Cd19+
Faslpr/Fastm1Cgn
Tg(Cd4-cre)1Cwi/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL 		enlarged lymph nodes J:114948
enlarged spleen J:114948
increased double-negative T cell number J:114948
Cd19tm1(cre)Cgn/Cd19+
Pax5tm1Mbu/Pax5tm3Mbu
involves: 129P2/OlaHsd * 129S2/SvPas 		abnormal B cell differentiation J:75504
abnormal class switch recombination J:75504
decreased IgG1 level J:75504
decreased IgG3 level J:75504
decreased IgG level J:75504
decreased immature B cell number J:75504
decreased immunoglobulin level J:75504
decreased mature B cell number J:75504
decreased pre-B cell number J:75504
Cd19tm1(cre)Cgn/Cd19+
Cxcr4tm1Tng/Cxcr4tm2Tng
involves: 129P2/OlaHsd * C57BL/6 		decreased plasma cell number J:109147
Cd19tm1(cre)Cgn/Cd19+
Gna11tm1Soff/Gna11tm1Soff
Gnaqtm2Soff/Gnaqtm2Soff
B6N.129-Cd19tm1(cre)Cgn Gna11tm1Soff Gnaqtm2Soff 		normal hematopoietic system phenotype J:117663
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae 		abnormal B cell negative selection J:155314
abnormal B cell physiology J:83213
abnormal class switch recombination J:114881
abnormal plasma cell morphology J:114881
decreased IgG level J:114881
decreased spleen germinal center number J:83213
increased B cell apoptosis J:83213
increased B cell number J:83213
increased B cell proliferation J:83213, J:155314
increased B-1 B cell number J:83213
increased IgM level J:114881
increased marginal zone B cell number J:83213
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		abnormal peripheral B cell anergy J:155314
Cd19tm1(cre)Cgn/Cd19+
Gna12tm1Citb/Gna12tm1Citb
Gna13tm2.1Soff/Gna13tm2.1Soff
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6N 		abnormal B cell physiology J:117663
decreased marginal zone B cell number J:117663
Cd19tm1(cre)Cgn/Cd19+
Tnfsf13btm1Msc/Tnfsf13btm1Msc
Traf2tm1Rbr/Traf2tm1Rbr
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		increased follicular B cell number J:132877
increased marginal zone B cell number J:132877
Cd19tm1(cre)Cgn/Cd19+
Ltbtm1Avt/Ltbtm1Avt
involves: 129P2/OlaHsd * C57BL/6 		abnormal adaptive immunity J:79129
abnormal spleen B cell follicle morphology J:79129
abnormal spleen follicular dendritic cell network J:79129
decreased marginal zone B cell number J:79129
decreased spleen germinal center number J:79129
decreased spleen germinal center size J:79129
small Peyer's patches J:79129
Cd19tm1(cre)Cgn/Cd19+
Ltbtm1Avt/Ltbtm1Avt
Tg(Lck-cre)1Jtak/?
involves: 129P2/OlaHsd * C57BL/6 		absent follicular dendritic cells J:79129
Cd19tm1(cre)Cgn/Cd19+
Ikbkbtm2Mka/Ikbkbtm2Mka
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 		abnormal B cell activation J:82995
decreased B cell number J:82995
decreased B cell proliferation J:82995
decreased B-1 B cell number J:82995
decreased IgG level J:82995
decreased IgM level J:82995
decreased marginal zone B cell number J:82995
increased B cell apoptosis J:82995
Cd19tm1(cre)Cgn/Cd19+
Ikbkbtm2Cgn/Ikbkbtm2.1Cgn
involves: 129P2/OlaHsd * C57BL/6 		decreased B-1 B cell number J:79132
decreased follicular B cell number J:79132
decreased marginal zone B cell number J:79132
decreased mature B cell number J:79132
Cd19tm1(cre)Cgn/Cd19+
Ifnar1tm1Uka/Ifnar1tm1Uka
B6.129P2-Cd19tm1(cre)Cgn Ifnar1tm1Uka 		decreased IgG1 level J:129128
decreased IgG2a level J:129128
decreased IgG3 level J:129128
decreased IgM level J:129128
Cd19tm1(cre)Cgn/Cd19+
Igbp1tm1Imku/Y
involves: 129P2/OlaHsd 		abnormal B cell physiology J:74619
abnormal somatic hypermutation frequency J:74619
abnormal spleen germinal center morphology J:74619
decreased B cell number J:74619
decreased B cell proliferation J:74619
decreased follicular B cell number J:74619
decreased immunoglobulin level J:74619
decreased pre-B cell number J:74619
Cd19tm1(cre)Cgn/Cd19+
Notch2tm1.1Hhi/Notch2+
involves: 129P2/OlaHsd * C57BL/6 * CBA 		decreased marginal zone B cell number J:83476
Cd19tm1(cre)Cgn/Cd19+
Notch2tm2Hhi/Notch2tm1.1Hhi
involves: 129P2/OlaHsd * C57BL/6 * CBA 		abnormal spleen marginal zone morphology J:83476
absent marginal zone B cells J:83476
decreased transitional stage B cell number J:83476
Cd19tm1(cre)Cgn/Cd19+
Srsf3tm1Pjln/Srsf3tm1Pjln
involves: 129P2/OlaHsd * BALB/c 		decreased B cell number J:113645
Cd19tm1(cre)Cgn/Cd19+
Ikbkbtm1Cgn/Ikbkbtm1.1Cgn
involves: 129P2/OlaHsd * C57BL/6 		decreased B-1 B cell number J:79132
decreased follicular B cell number J:79132
decreased immature B cell number J:79132
decreased marginal zone B cell number J:79132
decreased mature B cell number J:79132
increased B cell proliferation J:79132
Cd19tm1(cre)Cgn/Cd19+
Ikbkgtm1.1Mpa/Y
involves: 129P2/OlaHsd * C57BL/6 		decreased B-1 B cell number J:79132
decreased follicular B cell number J:79132
decreased immature B cell number J:79132
decreased marginal zone B cell number J:79132
decreased mature B cell number J:79132
increased B cell proliferation J:79132
Cd19tm1(cre)Cgn/Cd19+
Mcl1tm2Sjk/Mcl1tm3Sjk
involves: 129P2/OlaHsd * 129X1/SvJ 		abnormal B cell differentiation J:86906
absent early pro-B cells J:86906
absent late pro-B cells J:86906
absent pre-B cells J:86906
arrested B cell differentiation J:86906
decreased B cell number J:86906
increased B cell apoptosis J:86906
Cd19tm1(cre)Cgn/Cd19+
Rac1tm1Tyb/Rac1tm1Tyb
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		normal immune system phenotype J:86765
Cd19tm1(cre)Cgn/Cd19+
Rac1tm1Tyb/Rac1tm1Tyb
Rac2tm1Mddw/Rac2tm1Mddw
involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 		arrested B cell differentiation J:86765
decreased B cell number J:86765
decreased B-1 B cell number J:86765
decreased follicular B cell number J:86765
decreased marginal zone B cell number J:86765
decreased transitional stage B cell number J:86765
Cd19tm1(cre)Cgn/Cd19+
Tgfbr2tm1Roes/Tgfbr2tm1Roes
involves: 129P2/OlaHsd * BALB/c 		abnormal B cell physiology J:90558
abnormal B-1 B cell morphology J:90558
abnormal B-1 B cell number J:90558
absent plasma cells J:90558
decreased IgA level J:90558
enlarged Peyer's patches J:90558
increased IgG level J:90558
increased IgM level J:90558
increased leukocyte cell number J:90558
Cd19tm1(cre)Cgn/Cd19+
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell differentiation J:172843
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd 		decreased B cell number J:92789
Cd19tm1(cre)Cgn/Cd19+
Traf2tm1Rbr/Traf2tm1Rbr
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:132877
increased follicular B cell number J:132877
increased marginal zone B cell number J:132877
lymph node hyperplasia J:132877
Cd19tm1(cre)Cgn/Cd19+
Traf2tm1Rbr/Traf2tm1Rbr
Traf3tm1Rbr/Traf3tm1Rbr
involves: 129P2/OlaHsd * C57BL/6 * SJL 		abnormal B cell physiology J:132877
increased marginal zone B cell number J:132877
Cd19tm1(cre)Cgn/Cd19+
Il10tm1Roer/Il10tm1Roer
involves: 129P2/OlaHsd 		abnormal CD8-positive, alpha-beta T cell physiology J:151551
abnormal myeloid leukocyte morphology J:151551
decreased circulating interleukin-10 level J:151551
increased B cell number J:151551
increased CD4-positive, alpha-beta T cell number J:151551
increased plasma cell number J:151551
Cd19tm1(cre)Cgn/Cd19+
Rbpjtm1Hon/Rbpjtm1Hon
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell differentiation J:76240
decreased marginal zone B cell number J:76240, J:121523
increased follicular B cell number J:76240, J:121523
increased IgG3 level J:76240
increased susceptibility to bacterial infection J:76240
increased susceptibility to bacterial infection induced morbidity/mortality J:76240
Cd19tm1(cre)Cgn/Cd19+
Rbpjtm1Hon/Rbpjtm1Hon
Spentm2.1Hon/Spentm2.1Hon
involves: 129P2/OlaHsd * C57BL/6 * CBA 		decreased marginal zone B cell number J:121523
increased follicular B cell number J:121523
Cd19tm1(cre)Cgn/Cd19+
Fastm1Ach/Fastm1Ach
involves: 129P2/OlaHsd * BALB/c 		enlarged spleen J:123556
increased anti-nuclear antigen antibody level J:123556
increased immunoglobulin level J:123556
increased lymphocyte cell number J:123556
Cd19tm1(cre)Cgn/Cd19+
Klhl6tm2Sato/Klhl6tm2Sato
either: (involves: 129P2/OlaHsd * 129T2/SvEms) or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * CD-1) 		abnormal B cell differentiation J:101363
abnormal lymph node germinal center morphology J:101363
decreased B cell number J:101363
Cd19tm1(cre)Cgn/Cd19+
Prdm1tm1Clme/Prdm1tm1Clme
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ 		abnormal B cell differentiation J:101890
abnormal memory B cell number J:101890
abnormal plasma cell differentiation J:101890
abnormal plasma cell morphology J:101890, J:114881
decreased IgG level J:101890
decreased IgM level J:101890
decreased immunoglobulin level J:101890
decreased plasma cell number J:101890
increased spleen germinal center number J:101890
increased spleen germinal center size J:101890
Cd19tm1(cre)Cgn/Cd19+
Tnftm2.1Gkl/Tnftm2.1Gkl
involves: 129P2/OlaHsd * 129S/SvEv * 129S6/SvEvTac * C57BL/6J 		normal immune system phenotype J:108572
Cd19tm1(cre)Cgn/Cd19+
Ube2ntm1Aki/Ube2ntm1Aki
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:112287
abnormal humoral immune response J:112287
abnormal spleen marginal zone morphology J:112287
decreased B cell number J:112287
decreased B cell proliferation J:112287
decreased immunoglobulin level J:112287
decreased marginal zone B cell number J:112287
increased B cell apoptosis J:112287
Cd19tm1(cre)Cgn/Cd19+
Map3k7tm1Aki/Map3k7tm1.1Aki
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:112597
decreased B cell proliferation J:112597
decreased B-1 B cell number J:112597
decreased IgG1 level J:112597
decreased IgG3 level J:112597
decreased IgG level J:112597
decreased immunoglobulin level J:112597
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(CTNNB1)Nerl/Gt(ROSA)26Sortm1(CTNNB1)Nerl
involves: 129P2/OlaHsd * BALB/c 		normal immune system phenotype J:112660
Cd19tm1(cre)Cgn/Cd19+
Pdia3tm1Gjh/Pdia3tm1Gjh
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:112606
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:113365
abnormal splenic cell ratio J:113365
decreased B cell apoptosis J:113365
increased B cell number J:113365
increased cell proliferation J:113365
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 		normal immune system phenotype J:113365
Cd19tm1(cre)Cgn/Cd19+
Spi1tm2Dgt/Spi1tm2Dgt
involves: 129P2/OlaHsd * C57BL/6 		normal hematopoietic system phenotype J:114150
Cd19tm1(cre)Cgn/Cd19+
Fastm1Cgn/Fastm1Cgn
B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn 		increased anti-single stranded DNA antibody level J:114948
Cd19tm1(cre)Cgn/Cd19+
Spentm2.1Hon/Spentm2.1Hon
involves: 129P2/OlaHsd * C57BL/6 * CBA 		decreased follicular B cell number J:121523
increased marginal zone B cell number J:121523
Cd19tm1(cre)Cgn/Cd19+
Inpp5dtm1Rav/Inpp5dtm1Rav
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae 		abnormal B cell morphology J:166155
abnormal B cell physiology J:166155
abnormal coat appearance J:166155
abnormal myeloid leukocyte morphology J:166155
decreased B cell number J:166155
enlarged spleen J:166155
hunched posture J:166155
increased B cell number J:166155
increased B cell proliferation J:166155
increased follicular lymphoma incidence J:166155
increased lymphoma incidence J:166155
increased malignant tumor incidence J:166155
increased plasmacytoma incidence J:166155
increased spleen white pulp amount J:166155
increased splenic marginal zone lymphoma incidence J:166155
lethargy J:166155
premature death J:166155
weight loss J:166155
Cd19tm1(cre)Cgn/Cd19+
Ptpn6tm1Rsky/Ptpn6tm1Rsky
involves: 129P2/OlaHsd * C57BL/6 		abnormal humoral immune response J:123568
abnormal immune system physiology J:123568
abnormal leukocyte cell number J:123568
abnormal lymph organ size J:123568
decreased B cell proliferation J:123568
decreased follicular B cell number J:123568
decreased marginal zone B cell number J:123568
enlarged lymph nodes J:123568
enlarged spleen J:123568
increased B cell number J:123568
increased B-1a cell number J:123568
increased granulocyte number J:123568
increased macrophage cell number J:123568
increased plasma cell number J:123568
increased susceptibility to systemic lupus erythematosus J:123568
increased T cell number J:123568
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1Uzs/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * BALB/c 		normal immune system phenotype J:130768
Cd19tm1(cre)Cgn/Cd19+
Traf3tm1Rbr/Traf3tm1Rbr
involves: 129P2/OlaHsd * C57BL/6 * SJL 		abnormal B cell physiology J:132877
increased follicular B cell number J:132877
increased marginal zone B cell number J:132877
lymph node hyperplasia J:132877
Cd19tm1(cre)Cgn/Cd19+
Pbx1tm2Mlc/Pbx1tm2Mlc
involves: 129P2/OlaHsd * 129S6/SvEvTac 		no abnormal phenotype detected J:132963
Cd19tm1(cre)Cgn/Cd19+
Tcf3tm1Mbu/Tcf3tm1.2Mbu
involves: 129P2/OlaHsd * C57BL/6 * SJL 		decreased B cell number J:137719
decreased immature B cell number J:137719
decreased mature B cell number J:137719
decreased pre-B cell number J:137719
decreased pro-B cell number J:137719
decreased transitional stage B cell number J:137719
Cd19tm1(cre)Cgn/Cd19+
Tcf3tm1Mbu/Tcf3tm1.2Mbu
Tg(Vav-BCL2)69Jad/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL 		decreased pre-B cell number J:137719
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm5(Map3k14)Rsky/Gt(ROSA)26Sortm5(Map3k14)Rsky
involves: 129P2/OlaHsd * C57BL/6 		enlarged lymph nodes J:139293
enlarged spleen J:139293
increased marginal zone B cell number J:139293
increased mature B cell number J:139293
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm5(Map3k14)Rsky/Gt(ROSA)26Sortm5(Map3k14)Rsky
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 		decreased lymphocyte cell number J:139293
decreased mature B cell number J:139293
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm6(Map3k14*)Rsky/Gt(ROSA)26Sortm6(Map3k14*)Rsky
involves: 129P2/OlaHsd * C57BL/6 		abnormal Peyer's patch morphology J:139293
abnormal spleen B cell follicle morphology J:139293
decreased B-1 B cell number J:139293
enlarged lymph nodes J:139293
enlarged spleen J:139293
increased mature B cell number J:139293
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm6(Map3k14*)Rsky/Gt(ROSA)26Sortm6(Map3k14*)Rsky
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 		increased lymphocyte cell number J:139293
increased mature B cell number J:139293
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(Cd74/MOG)Awai/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:140751
decreased susceptibility to experimental autoimmune encephalomyelitis J:140751
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(Cd74/MOG)Awai/Gt(ROSA)26Sor+
Il10tm1Roer/Il10tm1Roer
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:140751
decreased susceptibility to experimental autoimmune encephalomyelitis J:140751
Cd19tm1(cre)Cgn/Cd19+
Kmt2atm1.1Erns/Kmt2atm1.1Erns
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL 		normal immune system phenotype J:147265
Cd19tm1(cre)Cgn/Cd19+
Ep300tm2Reck/Ep300+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 		abnormal adaptive immunity J:147840
abnormal B cell differentiation J:147840
abnormal humoral immune response J:147840
abnormal renal glomerulus morphology J:147840
abnormal spleen marginal zone macrophage morphology J:147840
abnormal transitional stage B cell morphology J:147840
arteritis J:147840
decreased B cell proliferation J:147840
decreased marginal zone B cell number J:147840
enlarged lymph nodes J:147840
enlarged spleen J:147840
extramedullary hematopoiesis J:147840
glomerulonephritis J:147840
increased activated T cell number J:147840
increased anti-double stranded DNA antibody level J:147840
increased B cell apoptosis J:147840
increased B cell number J:147840
increased IgG2b level J:147840
increased immunoglobulin level J:147840
increased megakaryocyte cell number J:147840
increased spleen weight J:147840
increased susceptibility to systemic lupus erythematosus J:147840
intermingled spleen red and white pulp J:147840
kidney inflammation J:147840
premature death J:147840
renal fibrosis J:147840
renal glomerular protein deposits J:147840
Cd19tm1(cre)Cgn/Cd19+
Ep300tm2Reck/Ep300+
involves: 129/Sv * 129P2/OlaHsd * FVB/N 		increased susceptibility to systemic lupus erythematosus J:147840
premature death J:147840
Cd19tm1(cre)Cgn/Cd19+
Slc3a2tm1.1Mgin/Slc3a2tm1.1Mgin
involves: 129 * C57BL/6 * SJL 		abnormal B cell activation J:148000
abnormal B cell physiology J:148000
abnormal class switch recombination J:148000
abnormal plasma cell differentiation J:148000
decreased B cell proliferation J:148000
decreased germinal center B cell number J:148000
decreased IgG level J:148000
decreased IgM level J:148000
normal immune system phenotype J:148000
Cd19tm1(cre)Cgn/Cd19+
Slc3a2tm1.1Mgin/Slc3a2tm1Yai
involves: 129 * C57BL/6 * SJL 		decreased IgG3 level J:148000
decreased IgM level J:148000
Cd19tm1(cre)Cgn/Cd19+
Mirc30tm1.1Rdf/Mirc30tm1.1Rdf
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6 		increased B cell derived lymphoma incidence J:156946
increased B cell number J:156946
increased B-1a cell number J:156946
increased leukemia incidence J:156946
increased spleen white pulp amount J:156946
Cd19tm1(cre)Cgn/Cd19+
Il10ratm1.1Jack/Il10ratm1.1Jack
involves: 129P2/OlaHsd * BALB/c * C57BL/6 		normal immune system phenotype J:157787
Cd19tm1(cre)Cgn/Cd19+
Ltbrtm1Avt/Ltbrtm1Avt
involves: 129P2/OlaHsd 		normal immune system phenotype J:158663
Cd19tm1(cre)Cgn/Cd19+
Ltbrtm1Avt/Ltbrtm1Avt
Tg(Lck-cre)I57Jxm/0
involves: 129P2/OlaHsd 		normal immune system phenotype J:158663
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd 		abnormal T cell activation J:160931
cachexia J:160931
enlarged spleen J:160931
increased T cell derived lymphoma incidence J:160931
increased T cell proliferation J:160931
premature death J:160931
Cd19tm1(cre)Cgn/Cd19+
Tnfaip3tm2Ama/Tnfaip3+
involves: 129P2/OlaHsd * C57BL/6 		decreased B cell apoptosis J:163917
increased autoantibody level J:163917
increased germinal center B cell number J:163917
increased immunoglobulin level J:163917
increased plasma cell number J:163917
increased susceptibility to autoimmune disorder J:163917
Cd19tm1(cre)Cgn/Cd19+
Rapgef2tm1.1Hous/Rapgef2tm1.1Hous
involves: 129P2/OlaHsd * 129S1/Sv 		normal hematopoietic system phenotype J:165879
normal immune system phenotype J:165879
Cd19tm1(cre)Cgn/Cd19+
Irf8tm1.1Hm/Irf8tm1.1Hm
involves: 129P2/OlaHsd * C57BL/6 		abnormal spleen marginal zone morphology J:168923
decreased follicular B cell number J:168923
normal immune system phenotype J:168923
increased B cell number J:168923
increased B-2 B cell number J:168923
increased follicular B cell number J:168923
increased marginal zone B cell number J:168923
increased transitional stage B cell number J:168923
Cd19tm1(cre)Cgn/Cd19+
Derl2tm1.1Hpl/Derl2tm1.1Hpl
involves: 129P2/OlaHsd 		normal immune system phenotype J:170650
Cd19tm1(cre)Cgn/Cd19+
Cd1d1tm1.1Aben/Cd1d1tm1.1Aben
B6.Cg-Cd1d1tm1.1Aben Cd19tm1(cre)Cgn 		normal immune system phenotype J:183087
Cd19tm1(cre)Cgn/Cd19+
Tnfaip3tm1.1Awai/Tnfaip3tm1.1Awai
involves: 129P2/OlaHsd 		decreased B-1a cell number J:175422
decreased B-1b cell number J:175422
decreased marginal zone B cell number J:175422
decreased mature B cell number J:175422
enlarged spleen J:175422
increased anti-nuclear antigen antibody level J:175422
increased B cell number J:175422
increased B cell proliferation J:175422
increased follicular B cell number J:175422
increased germinal center B cell number J:175422
increased IgA level J:175422
increased IgG2a level J:175422
increased IgM level J:175422
increased splenocyte number J:175422
increased T cell number J:175422
Cd19tm1(cre)Cgn/Cd19+
Ptpn11tm1Ckq/Ptpn11+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J 		increased acute lymphoblastic leukemia incidence J:177285
increased B cell derived lymphoma incidence J:177285
premature death J:177285
Cd19tm1(cre)Cgn/Cd19+
Trp53tm1Yjc/Trp53tm1Yjc
involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6 		normal neoplasm J:195018
Cd19tm1(cre)Cgn/Cd19+
Ell2tm1.1Cmil/Ell2tm1.1Cmil
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		abnormal endoplasmic reticulum morphology J:234692
decreased IgA level J:234692
decreased IgG1 level J:234692
decreased IgM level J:234692
decreased immunoglobulin level J:234692
decreased mature B cell number J:234692
decreased plasma cell number J:234692
decreased transitional stage T1 B cell number J:234692
decreased transitional stage T2 B cell number J:234692
decreased transitional stage T3 B cell number J:234692
impaired humoral immune response J:234692
increased follicular B cell number J:234692
increased immature B cell number J:234692
increased pre-B cell number J:234692
increased pro-B cell number J:234692
Cd19tm1(cre)Cgn/Cd19+
Ell2tm2.1Cmil/Ell2tm2.1Cmil
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		decreased IgA level J:234692
decreased IgG1 level J:234692
decreased IgM level J:234692
decreased immunoglobulin level J:234692
decreased mature B cell number J:234692
Cd19tm1(cre)Cgn/Cd19+
Ctnnbl1tm1.1Crad/Ctnnbl1tm1.1Crad
involves: 129P2/OlaHsd * C57BL/6 * SJL 		decreased B cell proliferation J:232010
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd 		abnormal B cell activation J:228288
abnormal bone marrow cell number J:228288
abnormal plasmablast number J:228288
abnormal spleen morphology J:228288
enlarged lymph nodes J:228288
enlarged spleen J:228288
increased B cell derived lymphoma incidence J:228288
increased B cell number J:228288
increased B cell proliferation J:228288
increased plasma cell number J:228288
postnatal lethality, complete penetrance J:228288
spleen hyperplasia J:228288
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
Malt1tm1Mak/Malt1tm1Mak
involves: 129P2/OlaHsd 		normal immune system phenotype J:228288
normal mortality/aging J:228288
Cd19tm1(cre)Cgn/Cd19+
Myd88em1.1Rsky/Myd88+
involves: C57BL/6NTac 		abnormal splenic cell ratio J:308792
enlarged spleen J:308792
normal hematopoietic system phenotype J:308792
increased germinal center B cell number J:308792
increased IgM level J:308792
increased plasma cell number J:308792
Cd19tm1(cre)Cgn/Cd19+
Myd88em1.1Rsky/Myd88em1.1Rsky
involves: C57BL/6NTac 		increased B cell proliferation J:308792
Cd19tm1(cre)Cgn/Cd19+
Tbl1xr1tm1c(EUCOMM)Hmgu/Tbl1xr1tm1c(EUCOMM)Hmgu
Tg(Vav-BCL2)69Jad/0
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N 		abnormal B cell differentiation J:292118
abnormal lymphocyte morphology J:292118
abnormal spleen morphology J:292118
increased organ/body region tumor incidence J:292118
premature death J:292118
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ightm1Mnz/Ightm1Mnz
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:75653
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ightm2Mnz/Ightm2Mnz
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:75653
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae 		normal immune system phenotype J:83213
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Tg(IghelMD4)4Ccg/0
involves: 129P2/OlaHsd * C57BL/6 		decreased B cell number J:155314
normal immune system phenotype J:155314
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * C57BL/6 		decreased B cell number J:155314
normal immune system phenotype J:155314
Cd19tm1(cre)Cgn/?
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sortm1(HBEGF)Awai
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell morphology J:131076
abnormal bone marrow cell number J:131076
abnormal lymph node cell ratio J:131076
abnormal lymphocyte cell number J:131076
abnormal lymphocyte morphology J:131076
abnormal splenic cell ratio J:131076
absent immature B cells J:131076
absent mature B cells J:131076
Cd19tm1(cre/ERT2)Rsky/Cd19+
Myd88em1.1Rsky/Myd88+
involves: 129P2/OlaHsd * C57BL/6NTac 		increased IgM level J:308792
increased plasma cell number J:308792
Cd19tm1Tft/Cd19tm1Tft
Lyntm1Sor/Lyntm1Sor
involves: 129S4/SvJaeSor * C57BL/6 		abnormal humoral immune response J:71174
decreased anti-double stranded DNA antibody level J:71174
decreased B cell number J:71174
decreased B cell proliferation J:71174
decreased B-1 B cell number J:71174
decreased mature B cell number J:71174
decreased susceptibility to systemic lupus erythematosus J:71174
enlarged spleen J:71174
normal immune system phenotype J:71174
Cxcr4tm2Yzo/Cxcr4tm2Yzo
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd 		abnormal B cell differentiation J:94911
abnormal Peyer's patch follicle morphology J:94911
decreased B-1 B cell number J:94911
decreased B-2 B cell number J:94911
decreased immunoglobulin level J:94911
decreased mature B cell number J:94911
decreased plasma cell number J:94911
Cxcr4tm2Yzo/Cxcr4tm3.1Yzo
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd 		abnormal B cell differentiation J:167314
Del(14Trim13-Rnaseh2b)6Rdf/+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6 		abnormal lymphopoiesis J:179879
increased B cell number J:179879
increased chronic lymphocytic leukemia incidence J:179879
increased lymphoma incidence J:179879
increased small lymphocytic lymphoma incidence J:179879
premature death J:179879
Dhx15tm1c(EUCOMM)Wtsi/Dhx15tm1c(EUCOMM)Wtsi
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C3H * C57BL/6N 		abnormal B cell differentiation J:284624
decreased B cell number J:284624
decreased B cell proliferation J:284624
decreased pre-B cell number J:284624
decreased spleen weight J:284624
spleen hypoplasia J:284624
Ebf1tm1.1Rug/Ebf1tm1.1Rug
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * SJL 		decreased B-1 B cell number J:182210
decreased marginal zone B cell number J:182210
Ezh2tm1.1Nesh/Ezh2+
Cd19tm1(cre)Cgn/Cd19+
involves: 129 * 129P2/OlaHsd * C57BL/6 		abnormal spleen morphology J:239472
abnormal spleen white pulp morphology J:239472
enlarged lymph nodes J:239472
enlarged spleen J:239472
increased B cell derived lymphoma incidence J:239472
increased leukemia incidence J:239472
premature death J:239472
Ezh2tm1.1Nesh/Ezh2tm1.1Nesh
Cd19tm1(cre)Cgn/Cd19+
involves: 129 * 129P2/OlaHsd * C57BL/6 		enlarged lymph nodes J:239472
enlarged spleen J:239472
increased B cell derived lymphoma incidence J:239472
Ezh2tm1Tara/Ezh2tm1Tara
Cd19tm1(cre)Cgn/?
involves: 129P2/OlaHsd 		normal immune system phenotype J:83216
Faslpr/Faslpr
Hspa13tm1.1Smoc/Hspa13tm1.1Smoc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp 		decreased autoantibody level J:303927
decreased susceptibility to systemic lupus erythematosus J:303927
increased urine protein level J:303927
Fastm1Cgn/Fastm1Cgn
Cd19tm1(cre)Cgn/Cd19+
Tg(Cd4-cre)1Cwi/0
B6.Cg-Tg(Cd4-cre)1Cwi Cd19tm1(cre)Cgn Fastm1Cgn 		increased anti-single stranded DNA antibody level J:114948
Gt(ROSA)26Sortm1(CAG-Bcl3,-EGFP)Hoev/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd 		abnormal B cell differentiation J:208980
abnormal B-2 B cell morphology J:208980
abnormal class switch recombination J:208980
abnormal follicular B cell morphology J:208980
abnormal Peyer's patch germinal center morphology J:208980
abnormal transitional stage T3 B cell morphology J:208980
absent marginal zone B cells J:208980
decreased B cell apoptosis J:208980
decreased B cell proliferation J:208980
decreased B-1 B cell number J:208980
decreased B-1a cell number J:208980
decreased IgG1 level J:208980
decreased IgG2b level J:208980
decreased IgG3 level J:208980
decreased IgM level J:208980
decreased immature B cell number J:208980
decreased marginal zone B cell number J:208980
decreased transitional stage T1 B cell number J:208980
enlarged spleen J:208980
increased lymphocyte cell number J:208980
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
Rev3ltm1.1Diaz/Rev3ltm1.1Diaz
involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac 		abnormal class switch recombination J:188723
abnormal somatic hypermutation frequency J:188723
decreased B cell proliferation J:188723
normal immune system phenotype J:188723
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6) 		abnormal class switch recombination J:172031
absent spleen germinal center J:172031
decreased B cell apoptosis J:172031
decreased B cell number J:172031
decreased germinal center B cell number J:172031
decreased IgA level J:172031
decreased IgG1 level J:172031
decreased IgG2a level J:172031
decreased IgG3 level J:172031
decreased plasma cell number J:172031
decreased tumor-free survival time J:172031
enlarged spleen J:172031
increased B cell number J:172031
increased histiocytic sarcoma incidence J:172031
increased IgE level J:172031
increased macrophage cell number J:172031
increased marginal zone B cell number J:172031
increased sarcoma incidence J:172031
increased spleen weight J:172031
increased T cell number J:172031
increased tumor incidence J:172031
Gt(ROSA)26Sortm1(Ptpn22*)Draw/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		enlarged spleen J:201448
expanded mesangial matrix J:201448
glomerulonephritis J:201448
increased anti-double stranded DNA antibody level J:201448
increased autoantibody level J:201448
increased B cell number J:201448
increased germinal center B cell number J:201448
spleen hyperplasia J:201448
Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J 		abnormal B cell differentiation J:179036
abnormal marginal zone B cell physiology J:179036
abnormal spleen marginal zone morphology J:179036
decreased B cell number J:179036
decreased B-1a cell number J:179036
decreased B-2 B cell number J:179036
decreased follicular B cell number J:179036
decreased IgG1 level J:179036
decreased IgG3 level J:179036
decreased IgM level J:179036
decreased spleen B cell follicle size J:179036
decreased spleen germinal center number J:179036
decreased transitional stage T2 B cell number J:179036
increased B cell proliferation J:179036
increased marginal zone B cell number J:179036
increased spleen weight J:179036
increased T cell number J:179036
increased transitional stage T1 B cell number J:179036
Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J 		abnormal B cell differentiation J:179036
abnormal spleen marginal zone morphology J:179036
decreased follicular B cell number J:179036
decreased mature B cell number J:179036
decreased pre-B cell number J:179036
decreased transitional stage T2 B cell number J:179036
increased marginal zone B cell number J:179036
increased transitional stage T1 B cell number J:179036
Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/c * C57BL/6 		abnormal B cell activation J:137122
abnormal B cell physiology J:137122
abnormal class switch recombination J:137122
abnormal humoral immune response J:137122
abnormal T cell activation J:137122
enlarged inguinal lymph nodes J:137122
enlarged liver J:137122
enlarged spleen J:137122
increased B cell derived lymphoma incidence J:137122
increased B cell number J:137122
increased B cell proliferation J:137122
increased follicular B cell number J:137122
increased marginal zone B cell number J:137122
increased spleen B cell follicle size J:137122
increased spleen weight J:137122
increased T cell number J:137122
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ 		enlarged spleen J:181546
increased B cell number J:181546
premature death J:181546
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ 		enlarged liver J:181546
enlarged spleen J:181546
increased B cell derived lymphoma incidence J:181546
increased B cell number J:181546
increased plasmacytoma incidence J:181546
premature death J:181546
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/cJ 		abnormal B cell differentiation J:181546
abnormal CD8-positive, alpha-beta T cell physiology J:181546
abnormal immune system physiology J:181546
decreased B cell number J:181546
decreased mature B cell number J:181546
decreased pre-B cell number J:181546
enlarged spleen J:181546
increased B cell number J:181546
increased B cell proliferation J:181546
increased CD4-positive, alpha-beta T cell number J:181546
increased CD8-positive, alpha-beta T cell number J:181546
increased pro-B cell number J:181546
increased susceptibility to induced morbidity/mortality J:181546
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 		normal neoplasm J:181546
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		enlarged spleen J:181546
increased B cell number J:181546
premature death J:181546
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		enlarged liver J:181546
enlarged spleen J:181546
increased B cell derived lymphoma incidence J:181546
increased B cell number J:181546
increased plasmacytoma incidence J:181546
premature death J:181546
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell differentiation J:181546
abnormal CD4-positive, alpha-beta T cell physiology J:181546
abnormal CD8-positive, alpha-beta T cell physiology J:181546
abnormal immune system physiology J:181546
decreased B cell number J:181546
decreased mature B cell number J:181546
decreased pre-B cell number J:181546
enlarged spleen J:181546
increased B cell number J:181546
increased B cell proliferation J:181546
increased CD4-positive, alpha-beta T cell number J:181546
increased CD8-positive, alpha-beta T cell number J:181546
increased interferon-gamma secretion J:181546
increased pro-B cell number J:181546
increased susceptibility to induced morbidity/mortality J:181546
increased tumor necrosis factor secretion J:181546
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		normal neoplasm J:181546
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre/ERT2)Rsky/Cd19+
involves: 129P2/OlaHsd * C57BL/6J 		abnormal T cell physiology J:217520
enlarged spleen J:217520
increased activated T cell number J:217520
increased B cell number J:217520
increased CD4-positive, alpha-beta T cell number J:217520
increased CD8-positive, alpha-beta T cell number J:217520
H2-Ab1b-tm1Wug/H2-Ab1b-tm1Wug
Cd19tm1(cre)Cgn/Cd19+
involves: 129S2/SvPas * C57BL/6 		abnormal B cell physiology J:204951
abnormal dendritic cell physiology J:204951
decreased susceptibility to experimental autoimmune encephalomyelitis J:204951
normal immune system phenotype J:204951
Hspa13tm1.1Smoc/Hspa13tm1.1Smoc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S * C57BL/6 		abnormal class switch recombination J:303927
abnormal humoral immune response J:303927
abnormal plasmablast number J:303927
abnormal somatic hypermutation frequency J:303927
decreased autoantibody level J:303927
decreased IgA level J:303927
decreased IgE level J:303927
decreased IgG1 level J:303927
decreased IgG2b level J:303927
decreased IgG2c level J:303927
decreased IgG3 level J:303927
decreased IgG level J:303927
decreased IgM level J:303927
decreased plasma cell number J:303927
decreased susceptibility to injury J:303927
increased urine protein level J:303927
Is(14)1Rdf/Is(14)1Rdf
Is(14)5Rdf/Is(14)5Rdf
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6 		abnormal lymphopoiesis J:179879
increased B cell number J:179879
increased chronic lymphocytic leukemia incidence J:179879
increased lymphoma incidence J:179879
increased small lymphocytic lymphoma incidence J:179879
premature death J:179879
Is(14)1Rdf Is(14)2Rdf/Del(14Trim13-Dleu2)4Rdf
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6 		increased B cell derived lymphoma incidence J:156946
increased B cell number J:156946
increased B-1a cell number J:156946
increased leukemia incidence J:156946
increased spleen white pulp amount J:156946
Is(14)1Rdf Is(14)5Rdf/Del(14Trim13-Rnaseh2b)6Rdf
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6 		abnormal lymphopoiesis J:179879
increased B cell number J:179879
increased chronic lymphocytic leukemia incidence J:179879
increased lymphoma incidence J:179879
increased small lymphocytic lymphoma incidence J:179879
premature death J:179879
Itgavtm2Hyn/Itgavtm2.1Hyn
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB 		normal digestive/alimentary phenotype J:125508
Kmt2dtm1.1Kaig/Kmt2d+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		increased germinal center B cell number J:228913
increased spleen germinal center size J:228913
Kmt2dtm1.1Kaig/Kmt2dtm1.1Kaig
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell differentiation J:228913
decreased B cell number J:228913
decreased follicular B cell number J:228913
decreased IgG1 level J:228913
decreased IgM level J:228913
decreased mature B cell number J:228913
normal immune system phenotype J:228913
increased B cell proliferation J:228913
increased germinal center B cell number J:228913
increased spleen germinal center number J:228913
increased spleen germinal center size J:228913
Lmo2tm3Thr/Lmo2tm4Thr
Cd19tm1(cre)Thr/Cd19+
involves: 129S/SvEv 		normal hematopoietic system phenotype J:86869
normal immune system phenotype J:86869
Map3k14tm1.1Gne/Map3k14tm1.1Gne
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac 		decreased B cell number J:280549
Map3k14tm1.1Gne/Map3k14tm1.1Gne
Otub1tm1c(EUCOMM)Hmgu/Otub1tm1c(EUCOMM)Hmgu
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * C57BL/6NTac 		normal immune system phenotype J:280549
Mcm3aptm1Imku/Mcm3aptm1Imku
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * CBA 		abnormal germinal center B cell physiology J:88276
abnormal memory B cell number J:88276
abnormal spleen germinal center morphology J:88276
decreased B cell number J:88276
decreased B cell proliferation J:88276
decreased germinal center B cell number J:88276
decreased IgG level J:88276
Mir148atm2942.1Arte/Mir148atm2942.1Arte
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		abnormal plasmablast number J:307366
decreased IgA level J:307366
decreased IgG level J:307366
decreased IgM level J:307366
decreased plasma cell number J:307366
impaired humoral immune response J:307366
increased memory B cell number J:307366
Myctm2Fwa/Myctm2Fwa
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac 		decreased B cell proliferation J:67222
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		normal immune system phenotype J:195140
Nabp2tm1.1Nfel/Nabp2tm1.2Nfel
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL 		normal immune system phenotype J:190019
Nfkb2Lym1/Nfkb2+
Otub1tm1c(EUCOMM)Hmgu/Otub1tm1c(EUCOMM)Hmgu
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/c * C57BL/6 * C57BL/6N 		normal immune system phenotype J:280549
Nle1tm1Cba/Nle1tm1.1Cota
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas 		normal hematopoietic system phenotype J:204063
normal immune system phenotype J:204063
Otub1tm1c(EUCOMM)Hmgu/Otub1tm1c(EUCOMM)Hmgu
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N 		abnormal B cell activation J:280549
abnormal follicular B cell morphology J:280549
decreased B-1 B cell number J:280549
decreased immature B cell number J:280549
decreased T cell number J:280549
enlarged spleen J:280549
increased anti-double stranded DNA antibody level J:280549
increased anti-nuclear antigen antibody level J:280549
increased B cell number J:280549
increased B-2 B cell number J:280549
increased circulating interleukin-6 level J:280549
increased IgA level J:280549
increased IgG2a level J:280549
increased IgG2b level J:280549
increased IgM level J:280549
increased immunoglobulin level J:280549
increased marginal zone B cell number J:280549
increased mature B cell number J:280549
increased susceptibility to autoimmune disorder J:280549
increased susceptibility to systemic lupus erythematosus J:280549
Palb2tm1.1Dli/Palb2tm1.1Dli
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 		chromosome breakage J:197442
Pax5tm3Mbu/Pax5+
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		abnormal pro-B cell morphology J:226241
arrested B cell differentiation J:226241
decreased immature B cell number J:226241
increased B cell acute lymphoblastic leukemia incidence J:226241
Pcid2tm1Imku/Pcid2tm1Imku
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * CBA 		abnormal spleen B cell follicle morphology J:166080
decreased follicular B cell number J:166080
decreased marginal zone B cell number J:166080
decreased mature B cell number J:166080
Pdap1em1Rkuhn/Pdap1em1Rkuhn
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N 		abnormal B cell physiology J:298705
abnormal class switch recombination J:298705
abnormal mitochondrial physiology J:298705
abnormal somatic hypermutation frequency J:298705
decreased germinal center B cell number J:298705
decreased mature B cell number J:298705
increased B cell apoptosis J:298705
Pgap3tm1Ymra/Pgap3tm1Ymra
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd 		normal immune system phenotype J:203443
Pik3cdtm1Tnr/Pik3cdtm1Tnr
Ptentm2.1Ppp/Ptentm2.1Ppp
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6 		abnormal class switch recombination J:130950
normal immune system phenotype J:130950
increased marginal zone B cell number J:130950
Pik3cdtm2.1Tnr/Pik3cdtm2.1Tnr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		normal immune system phenotype J:164283
increased IgE level J:164283
Prelid1tm1Hmva/Prelid1tm1Hmva
Cd19tm1(cre)Cgn/Cd19+
involves: 129 * 129P2/OlaHsd * C57BL/6 		no abnormal phenotype detected J:187294
Ptpmt1tm2.1Ckq/Ptpmt1tm2.1Ckq
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL 		normal hematopoietic system phenotype J:194929
normal immune system phenotype J:194929
Rbbp8tm1Whl/Rbbp8tm1.1Thl
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S4/SvJaeSor 		normal immune system phenotype J:194603
Rc3h1tm1.1Mass/Rc3h1tm1.1Mass
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * NZB * SJL 		abnormal effector T cell morphology J:177784
enlarged spleen J:177784
increased B cell number J:177784
increased eosinophil cell number J:177784
increased regulatory T cell number J:177784
increased spleen weight J:177784
Rnaseh2btm1c(EUCOMM)Wtsi/Rnaseh2btm1c(EUCOMM)Wtsi
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL 		decreased B cell proliferation J:186986
normal immune system phenotype J:186986
Sh2d1atm2Vei/Sh2d1atm2Vei
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		normal immune system phenotype J:131618
Srftm2Nor/Srftm2Nor
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd 		abnormal mature B cell morphology J:124767
absent marginal zone B cells J:124767
decreased B cell number J:124767
decreased B-1 B cell number J:124767
Tab2tm2.1Aki/Tab2tm2.1Aki
Tab3tm1Aki/Tab3tm1Aki
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:195289
abnormal immune serum protein physiology J:195289
decreased B cell proliferation J:195289
decreased B-1a cell number J:195289
decreased circulating interleukin-6 level J:195289
decreased IgD level J:195289
decreased IgE level J:195289
decreased IgG level J:195289
decreased immunoglobulin level J:195289
decreased mature B cell number J:195289
decreased plasma cell number J:195289
increased B cell apoptosis J:195289
Tbk1tm1Arte/Tbk1tm1Arte
Cd19tm1(cre)Cgn/Cd19+
involves: 129/SvEv * 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:188560
abnormal class switch recombination J:188560
abnormal kidney physiology J:188560
increased anti-double stranded DNA antibody level J:188560
increased anti-nuclear antigen antibody level J:188560
increased blood urea nitrogen level J:188560
increased circulating creatinine level J:188560
increased IgA level J:188560
increased IgM level J:188560
increased mature B cell number J:188560
increased urine protein level J:188560
Tbk1tm1Arte/Tbk1tm1Arte
Map3k14tm1Rds/Map3k14tm1Rds
Cd19tm1(cre)Cgn/Cd19+
involves: 129/SvEv * 129P2/OlaHsd * C57BL/6 		abnormal B cell differentiation J:188560
abnormal immunoglobulin level J:188560
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:226241
abnormal pro-B cell differentiation J:226241
abnormal pro-B cell morphology J:226241
anemia J:226241
arrested B cell differentiation J:226241
decreased B cell number J:226241
decreased immature B cell number J:226241
enlarged liver J:226241
enlarged lymph nodes J:226241
enlarged spleen J:226241
increased B cell acute lymphoblastic leukemia incidence J:226241
increased leukocyte cell number J:226241
thrombocytopenia J:226241
Tnftm1.1Sned/Tnftm1.1Sned
Cd19tm1(cre)Cgn/Cd19+
involves: 129 * 129P2/OlaHsd * C57BL/6 		normal immune system phenotype J:95684
Tnfaip3tm2Ama/Tnfaip3tm2Ama
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell activation J:163917
abnormal B cell morphology J:163917
abnormal B-1a B cell morphology J:163917
decreased B cell apoptosis J:163917
decreased B cell number J:163917
increased autoantibody level J:163917
increased B cell number J:163917
increased B cell proliferation J:163917
increased germinal center B cell number J:163917
increased IgG level J:163917
increased IgM level J:163917
increased immature B cell number J:163917
increased immunoglobulin level J:163917
increased interleukin-6 secretion J:163917
increased plasma cell number J:163917
increased susceptibility to autoimmune disorder J:163917
increased T cell number J:163917
Traf3tm1Bshp/Traf3tm1Bshp
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL 		abnormal adaptive immunity J:124329
abnormal immune system organ morphology J:124329
abnormal immune system physiology J:124329
abnormal kidney morphology J:124329
abnormal leukocyte morphology J:124329
abnormal liver morphology J:124329
abnormal lymph node B cell domain morphology J:124329
abnormal spleen germinal center morphology J:124329
autoimmune response J:124329
decreased B cell apoptosis J:124329
decreased physiological sensitivity to xenobiotic J:124329
decreased T cell number J:124329
enlarged lymph nodes J:124329
enlarged spleen J:124329
increased anti-double stranded DNA antibody level J:124329
increased B cell number J:124329
increased follicular B cell number J:124329
increased IgA level J:124329
increased IgG2a level J:124329
increased IgG2b level J:124329
increased IgG3 level J:124329
increased IgG level J:124329
increased IgM level J:124329
increased marginal zone B cell number J:124329
increased spleen white pulp amount J:124329
increased transitional stage B cell number J:124329
Zc3h12ctm2c(EUCOMM)Hmgu/Zc3h12ctm2c(EUCOMM)Hmgu
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N 		normal immune system phenotype J:277714
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/19/2024
MGI 6.24 		The Jackson Laboratory